Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX),
a specialty pharmaceutical company focused on the development and
commercialization of novel prescription drugs targeting rare (orphan)
neuromuscular and neurological diseases, today provided an update on its
progress with its lead investigational product, FIRDAPSETM.
The target price for this stock is $2.5, I believe once the drug gets approved it will shoot up to $10 by 2015
This stock is undervalue, FIRDAPSE was approved and already selling in Europe. It is just a matter of time this stock will get approved in U.S
Buy it when it is undervalued.
Look at the chart it is well headed towards $2. It is a strong buy!!!
website for the stock http://ir.catalystpharma.com/
The target price for this stock is $2.5, I believe once the drug gets approved it will shoot up to $10 by 2015
This stock is undervalue, FIRDAPSE was approved and already selling in Europe. It is just a matter of time this stock will get approved in U.S
Buy it when it is undervalued.
Look at the chart it is well headed towards $2. It is a strong buy!!!
website for the stock http://ir.catalystpharma.com/
No comments:
Post a Comment